Ralf Langhoff

Ralf Langhoff

Auto-generated profile, based on publicly available information

Ralf Langhoff

Department of Angiology, Center for Internal Medicine I, Campus Clinic Brandenburg, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in Vasa
Verified
Journal Article
Closed access
Korosoglou GrigoriosKorosoglou Grigorios
Korosoglou Grigorios
ASAndrej Schmidt
Andrej Schmidt
MLMichael Lichtenberg
Michael Lichtenberg
GTGiovanni Torsello
Giovanni Torsello
GGGerd Grözinger
Gerd Grözinger
RLRalf Langhoff
Ralf Langhoff
Summary: Together with colleagues from different disciplines, including cardiologists, interventional radiologists and vascular surgeons, committee members of the of the German Society of Angiology ( Deutsche Gesellschaft für Angiologie [ DGA]), developed a novel algorithm for the endovascular treatment of peripheral chronic total occlusive lesions (CTOs). Our aim is to improve patient and limb related outcomes, by increasing the success rate of endovascular procedures. This can be achieved by adherence to the proposed crossing algorithm, aiding the standardization of endovascular procedures. The following steps are proposed: (i) APPLY Duplex sonography and if required 3D techniques such as computed tomography or magnetic resonance angiography. This will help you to select the optimal access site. (ii) EVALUATE the CTO cap morphology and distal vessel refilling sites during diagnostic angiography, which are potential targets for a retrograde access. (iii) START with antegrade wiring strategies including guidewire (GW) and support catheter technology. Use GW escalation strategies to penetrate the proximal cap of the CTO, which may usually be fibrotic and calcified. (iv) STOP the antegrade attempt depending on patient specific parameters and the presence of retrograde options, as evaluated by pre-procedural imaging and during angiography. (v) In case of FAILURE, consider advanced bidirectional techniques and reentry devices. (vi) In case of SUCCESS, externalize the GW and treat the CTO. Manage the retrograde access at the end of the endovascular procedure. (vii) STOP the procedure if no progress can be obtained within 3 hours, in case of specific complications or when reaching maximum contrast administration based on individual patient’s renal function. Consider radiation exposure both for patients and operators. In this manuscript we systematically follow and explain each of the steps (i)–(vi) based on practical examples from our daily routine. We strongly believe that the integration of this algorithm in the daily practice of endovascular specialists, can improve vessel and patient specific outcomes.

1 February 2019 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
RLRalf Langhoff
Ralf Langhoff
JSJoachim Schofer
Joachim Schofer
DSDierk Scheinert
Dierk Scheinert
ASAndrej Schmidt
Andrej Schmidt
GSGerald Sedgewick
Gerald Sedgewick
TZThomas Zeller
Thomas Zeller

1 January 2010 in EuroIntervention
Verified
Journal Article
Closed access
KSKarl-Ludwig Schulte
Karl-Ludwig Schulte
SMStefan Müller-Hülsbeck
Stefan Müller-Hülsbeck
PCPiergiorgio Cao
Piergiorgio Cao
JBJean-Pierre Becquemin
Jean-Pierre Becquemin
RLRalf Langhoff
Ralf Langhoff
JBJean-Paul Beregi
Jean-Paul Beregi
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

24 March 2022 in Angiology
Verified
Journal Article
Closed access
Korosoglou GrigoriosKorosoglou Grigorios
Korosoglou Grigorios
SGSorin Giusca
Sorin Giusca
RLRalf Langhoff
Ralf Langhoff
MLMichael Lichtenberg
Michael Lichtenberg
HLHolger Lawall
Holger Lawall
NMNasser Malyar
Nasser Malyar
This study investigated the distribution of risk factors, lesion characteristics and endovascular revascularization (EVR) strategies in patients with peripheral arterial disease (PAD) with vs without diabetes mellitus (DM). Data were collected within the RECcording COurses of vasculaR Diseases (RECCORD) registry. Demographic data, lesion localization (iliac vs femoropopliteal vs below-the-knee (BTK)) and lesion complexity score (LCS) based on number of affected segments, and lesion length (< 10 vs 10–20 vs > 20 cm), EVR strategies and peri-procedural complications were analysed in 786 patients with and 1337 without diabetes mellitus. Patients with diabetes mellitus were older (71.6 ± 9.6 vs 69.4 ± 10.5 years, P < .001) and had higher LCS and more often BTK lesions ( P < .05 for all). Lesions were treated less frequently with stents (48.7 vs 59.6%, P < .001) in patients with diabetes mellitus, whereas a non-significant trend was noticed for higher DCB treatment rates (48.3 vs 44.4%, P = .07). Post-interventional ankle-brachial index (ABI) increase was similar (from .77 ± .28 to .92 ± .25 with diabetes mellitus and from .74 ± .21 to .90 ± .20 without diabetes mellitus, P < .001 for both). Peri-/post-procedural complications were low in both groups (4.6%). Patients with diabetes mellitus, who undergo endovascular revascularization are older, have more comorbidities and higher target lesion complexity. However, treatment success rates are similar and complication rates are low.

13 October 2022 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
RLRalf Langhoff
Ralf Langhoff
Ivo PetrovIvo Petrov
Ivo Petrov
SKSasko Kedev
Sasko Kedev
ZMZoran Milosevic
Zoran Milosevic
ASAndrej Schmidt
Andrej Schmidt
AMAntonio Micari
Antonio Micari
Objectives: The PERFORMANCE I study was designed to evaluate the safety and feasibility of the Neuroguard IEP® System, a novel carotid stent system with an integrated embolic filter and post‐dilatation balloon, to treat clinically significant carotid artery stenosis.Background: The risk of major adverse events during carotid artery stenting is comparable to carotid endarterectomy, however, the risk of minor stroke remains higher with stenting.Methods: In total, 67 patients undergoing carotid artery stenting were enrolled at nine centers in Europe. Follow‐up assessments included neurological exams, duplex ultrasound, 12‐lead electrocardiogram, and cardiac enzyme analysis. The primary endpoint was the 30‐day composite rate of stroke, death, and myocardial infarctions versus a prespecified performance goal. Secondary endpoints included procedure success, device success, and target lesion revascularization.Results: The study population was predominantly male (74.6%) with a mean age of 69.3 ± 8.9 years and 67% of subjects met at least one criterion placing them at an elevated risk for adverse events following carotid endarterectomy. All patients were treated successfully with the study device. There were no deaths or strokes within 30 days of the index procedure. One subject (1.5%) experienced a non‐ST elevation myocardial infarction at day 17. The primary endpoint was met with a 30‐day major adverse events rate of 1.5% (1/67). Through 12‐month follow‐up, there were no strokes, neurological deaths, target lesion revascularizations, or instances of in‐stent‐restenosis.Conclusions: Results from this study demonstrate the Neuroguard IEP system is safe and feasible with a stroke/death rate of 0% at 30 days. A large pivotal study is currently underway.

29 March 2021 in Angiology
Verified
Journal Article
Closed access
PDF file
RLRalf Langhoff
Ralf Langhoff
JAJawed Arjumand
Jawed Arjumand
MWMatthias Waliszewski
Matthias Waliszewski
PRPeter Reimer
Peter Reimer
DHDirk Härtel
Dirk Härtel
GKGrigorios Korosoglou
Grigorios Korosoglou
We evaluated the safety and efficacy of a resveratrol-paclitaxel-coated peripheral balloon catheter in an all-comer patient cohort undergoing endovascular treatment of above-the-knee and below-the-knee peripheral artery disease. CONSEQUENT ALL COMERS (Clinical Post-Market Clinical Follow-up [PMCF] on Peripheral Arteries treated with SeQuent Please OTW [Over-the Wire]) is a prospective, single-arm, multicenter observational study (ClinicalTrials Identifier: NCT02460042). The primary end point was the 12-month target lesion revascularization (TLR) rate. Secondary end points included vessel patency, target vessel revascularization, and all-cause mortality. A total of 879 lesions in 784 consecutive patients (71.3 ± 10.4 years old, 57.7% male) were analyzed; 53.3% had claudication, whereas the remaining 46.7% exhibited critical limb ischemia (CLI). Substantial comorbidities were present, including diabetes mellitus (41.2%), smoking (66.1%), and coronary artery disease (33.9%). Lesion length (879 lesions) was 12.0 ± 9.3 cm and 31.8% were Transatlantic Inter-Society Consensus II C/D lesions. The overall technical success rate of the 1269 drug-coated balloon (DCB)’s used was 99.6% (1.60 ± 0.79 DCB’s/patient). At 12 months, the TLR rates were 6.3% in patients with CLI and 9.6% in claudicants, with a primary patency rate of 89.9% and 87.1%, respectively. All-cause mortality was 4.3% (28/658). The most important predictors for TLR were female gender, in-stent restenosis at baseline and lesion length.